Adverse events6,030

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 6,030

Type	Event	Organ system	Group	Affected	At risk	Events
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 1 (RCC) Phase 1b: Ibrutinib 560 mg + Everolimus	2	3	5
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 1 (RCC) Phase 1b: Ibrutinib 840 mg + Everolimus	2	7	16
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 1 (RCC) Phase 2: Ibrutinib 840 mg + Everolimus	19	38	58
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 2 (UC) Phase 1b: Ibrutinib 560 mg + Paclitaxel	1	4	1
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 2 (UC) Phase 1b: Ibrutinib 840 mg + Paclitaxel	4	10	7
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 2 (UC) Phase 2: Ibrutinib 840 mg + Paclitaxel	20	55	57
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 3 (GA) Phase 1b: Ibrutinib 560 mg + Docetaxel	8	21	32
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 3 (GA) Phase 2 (RP2D): Ibrutinib 560 mg + Docetaxel	16	31	33
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 4 (CA) Phase 1b: Ibrutinib 560 mg + Cetuximab	1	8	1
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 4 (CA) Phase 1b: Ibrutinib 840 mg + Cetuximab	1	12	1
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 4 (CA) Phase 2 (RP2D): Ibrutinib 840 mg + Cetuximab	5	44	9
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 5 (UC) Phase 1b: Ibrutinib 840 mg	0	10	0
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 5 (UC) Phase 2: Ibrutinib 840 mg	6	33	12
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 6 (UC) Phase 1b: Ibrutinib 560 mg + Pembrolizumab	0	17	0
other	ANAEMIA	Blood and lymphatic system disorders	Cohort 6 (UC) Phase 2: Ibrutinib 560 mg + Pembrolizumab	0	13	0
other	COAGULOPATHY	Blood and lymphatic system disorders	Cohort 1 (RCC) Phase 1b: Ibrutinib 560 mg + Everolimus	0	3	0
other	COAGULOPATHY	Blood and lymphatic system disorders	Cohort 1 (RCC) Phase 1b: Ibrutinib 840 mg + Everolimus	0	7	0
other	COAGULOPATHY	Blood and lymphatic system disorders	Cohort 1 (RCC) Phase 2: Ibrutinib 840 mg + Everolimus	0	38	0
other	COAGULOPATHY	Blood and lymphatic system disorders	Cohort 2 (UC) Phase 1b: Ibrutinib 560 mg + Paclitaxel	0	4	0
other	COAGULOPATHY	Blood and lymphatic system disorders	Cohort 2 (UC) Phase 1b: Ibrutinib 840 mg + Paclitaxel	0	10	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02599324/events

API reference For AI assistants

Adverse events6,030

Sources 3

Read this list from software.